Merck & Co Inc has announced plans to collaborate with the MD Anderson Cancer Center in Texas to investigate combinations of its checkpoint antibody Keytruda (pembrolizumab) with other agents as possible treatments for three solid tumours. ---Subscribe to MedNous to access this article--- Company News Clinical Research
